ZAGENO
ZAGENO Empowers Life Science Research with Unparalleled Efficiency and Cost Savings
CAMBRIDGE, MA / ACCESSWIRE / May 25, 2023 / ZAGENO, the leading online marketplace for life science research products, announces the completion of a $33 million funding round. General Catalyst, the largest public pension fund in the United States, Grazia Equity, OakRidge Management Group, and a German investment house led this round, joined by existing investors Capnamic Ventures and HighSage Ventures.
This funding propels ZAGENO's expansion in the United States and Europe, significantly enhancing the accessibility and affordability of life science research products. ZAGENO simplifies product discovery, experiment planning, and seamless purchasing from thousands of suppliers. The marketplace revolutionizes the scientific workflow, saving time and product costs. With a wide selection of quality products and verified suppliers, scientists benefit from competitive pricing fostered by the marketplace's transparency and supplier choice.
"We're thrilled to welcome new investors, including one of America's most powerful shareholder bodies and global leader in the investment industry and a prominent German investment house, while enjoying continued support from General Catalyst and existing investors," said Florian Wegener, CEO of ZAGENO. "This funding empowers scientists to focus on scientific value creation."
ZAGENO's online marketplace offers a vast selection of products and services, including laboratory equipment, consumables, chemicals, antibodies, and customized solutions. By providing scientists access to a network of verified suppliers, the ZAGENO platform enables informed purchasing decisions.
"ZAGENO is transforming the scientific research industry with its groundbreaking platform," said Larry Bohn, Managing Partner at General Catalyst. "We proudly support their journey."
"With this funding, ZAGENO is positioned to deliver even greater value to scientists worldwide," emphasized Joe von Rickenbach, Chairman of the Board of ZAGENO. "Their innovative platform drives unmatched efficiency and cost savings."
ZAGENO is primed for rapid growth and pioneering innovation in the scientific research industry with this new funding.
To learn more about ZAGENO, please visit www.zageno.com.
About ZAGENO
ZAGENO is a marketplace for life science research products. By revolutionizing how scientists discover, procure, and manage life science research products, ZAGENO supports researchers pursuing breakthroughs that improve our lives. With an extensive catalog, advanced search functionality, transparent pricing, and dedicated customer support, ZAGENO simplifies the research workflow and enables scientists to focus on groundbreaking discoveries. ZAGENO is a global company with offices in Cambridge, San Francisco, Berlin, and Bangalore. For more information, visit www.zageno.com.
About General Catalyst
General Catalyst is a venture capital firm that invests in powerful, positive change that endures - for our entrepreneurs, our investors, our people, and society. We support founders with a long-term view who challenge the status quo, partnering with them from seed to growth stage and beyond to build companies that withstand the test of time. With offices in San Francisco, Palo Alto, New York City, London, and Boston, the firm has helped support the growth of businesses such as: Airbnb, Deliveroo, Guild, Gusto, Hubspot, Illumio, Lemonade, Livongo, Oscar, Samsara, Snap, Stripe, and Warby Parker. For more: www.generalcatalyst.com.
Contact Information
Stephanie Harold
pr@zageno.com
+1 (857) 477-8479
Related Files
Related Images
SOURCE: ZAGENO
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/757107/ZAGENO-Secures-33M-Funding-to-Revolutionize-Life-Science-Research-Procurement
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
eComplete Partners with Sourceful to build AI-Native Creative Operations Across Portfolio18.11.2025 15:00:00 CET | Press release
MANCHESTER, UK / ACCESS Newswire / November 18, 2025 / eComplete, the private equity firm behind Current Body's £300 million London Stock Exchange listing, has announced a strategic partnership with Sourceful, the Manchester-based technology company whose Riverflow 1 model ranks as the world's leading AI image editing model. The partnership brings Sourceful's AI-native creative platform to eComplete's portfolio of direct-to-consumer brands, enabling them to generate brand-accurate, production-ready creative assets at scale across e-commerce, social, marketplace and retail. This makes eComplete the first major private equity investor to adopt AI-native creative infrastructure as a core operational advantage. Why this matters Every consumer brand today faces the same constraint: producing thousands of creative assets, product images, ads, videos, packaging, that feel authentically on-brand across every channel and market. This challenge has intensified dramatically over the past three ye
IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release
Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres
General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release
DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom